Clinical Trials Logo

Retinal Perforations clinical trials

View clinical trials related to Retinal Perforations.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06323902 Completed - Macular Holes Clinical Trials

Autologous Platelet-rich Plasma as a Treatment for Macular Holes

Start date: October 25, 2022
Phase:
Study type: Observational

For a series of patients with full-thickness macular hole, an autologous plasma rich in growth factors was developed in the form of a clot and applied to the retinal defect. These patients were followed up for a period of one year, obtaining substantial improvement both anatomically and functionally.

NCT ID: NCT05897671 Completed - Clinical trials for Full Thickness Macular Hole

Foveal Sparing ILM Peeling With ILM Flap Transposition

Start date: June 1, 2023
Phase:
Study type: Observational

Foveal sparing internal limiting membrane (ILM) peeling with ILM flap transposition over the macular hole combines the benefits of foveal sparing ILM peeling with ILM flap techniques. Aim of this study is to retrospectively examine the rate of postsurgical macular hole closure, development of central atrophy in the foveal area, and improvement of best corrected distant visual acuity in a group of patients having undergone foveal sparing ILM peeling with ILM flap transposition for macular hole repair.

NCT ID: NCT05710458 Completed - Retinal Detachment Clinical Trials

Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This prospective randomised controlled trial will be conducted to investigate that increasing the vitrectomy cutting rate from 10,000 cut/min to 20,000 cut/min will result more efficiency and shorter core vitrectomy time, and it is equally safe as compared to the current 10,000 cut/min. We plan to target the patients undergoing for vitrectomy for common vitreoretinal pathology. Our plan is to conduct a randomised study with 2 arms, one with the higher cutting rate (20,000 cut/min) versus a second arm using the existing system 10,000 cuts/min.

NCT ID: NCT05517473 Completed - Macular Holes Clinical Trials

Efficacy and Safety Evaluation of MONOBLUE DUAL View and MONOBLUE ILM View Vital Stains

NewBlueDyes
Start date: July 5, 2022
Phase:
Study type: Observational

In this study, the investigators aim to collect data regarding the efficiency and safety of two dyes used intraoperatively in vitrectomy to stain intraocular tissues. These products have the necessary approvals to use during such operation,These are NOT experimental products.

NCT ID: NCT05269563 Completed - Macular Holes Clinical Trials

Double Flap Technique for Macular Hole

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Double flapping technique to close the macular hole.

NCT ID: NCT05223205 Completed - Macular Holes Clinical Trials

Optical Coherence Tomography Angiography Characteristics of Patients With Surgically Closed Full-thickness Idiopathic Macular Holes < 600 μm With Air Versus 10% SF6 Tamponade

Start date: July 6, 2020
Phase: N/A
Study type: Interventional

State of the art treatment for idiopathic macular holes consists of pars plana vitrectomy, internal limiting membrane staining with a blue colouring dye, internal limiting membrane peeling and filling of the vitrectomized space with a specific tamponade such as air and SF6. Air and SF6 have previously shown similar closure rates, although there was a trend towards lower closure rates in large diameter IMH (Idiopathic Macular Holes) using air. IMH with diameters < 600 μm are currently believed to have similar closure rates with air and SF6. The investigators want to assess possible effects of the used tamponade (air or SF6) on closure rates and perfusion parameters represented by OCTA (Optical coherence tomography angiography). IMH eyes with a minimum diameter > 600 μm will be excluded. Two idiopathic macular hole patient groups will therefore be formed: The first group (group 1) will receive air after vitrectomy and membrane peeling, the second group (group 2) will receive 10% SF6 (and 90% air) after vitrectomy and membrane peeling. After recruitment, patients will therefore be electronically randomized to one of the two groups. The groups will then be compared by the means of OCT (Optical coherence tomography) and OCTA. Note: The trial was registered retrospectively on Clinicaltrials.gov after start of recruitment.

NCT ID: NCT05171621 Completed - Epiretinal Membrane Clinical Trials

Measuring Subjective Quality of Vision and Metamorphopsia Before and After Epiretinal Membrane and Macular Hole Surgery

MQUEST
Start date: October 16, 2019
Phase:
Study type: Observational

Assessing metamorphopsia and quality of vision pre and post epiretinal and macular hole surgery

NCT ID: NCT05086588 Completed - Epiretinal Membrane Clinical Trials

Safety and Efficacy Evaluation of Two Different Brilliant Blue G Dyes as Staining Agent in Vitreo Retinal Surgery.

Start date: April 4, 2018
Phase:
Study type: Observational

This is a prospective, Open-label, comparative clinical study to asses two brilliant blue G dyes as staining agent in Vitro Retinal Surgery.

NCT ID: NCT04883697 Completed - Macular Holes Clinical Trials

Retrospective Evaluation of Risk Factors for Lower Outcomes After Vitrectomy With ILM Flap Technique

Start date: January 1, 2021
Phase:
Study type: Observational

A retrospective review of medical charts of patients having undergone vitrectomy with ILM Peeling and ILM flap technique for macular hole repair.

NCT ID: NCT04723160 Completed - Clinical trials for Diabetic Retinopathy

Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph

Start date: August 10, 2020
Phase:
Study type: Observational

Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma. Without timely diagnosis and adequate medical intervention, the visual impairment can become a great burden on individuals as well as the society. It is estimated that China has 110 million patients under the attack of diabetes, 180 million patients with hypertension, 120 million patients suffering from high myopia and 200 million people over 60 years old, which suggest a huge population at the risk of blindness. Despite of this crisis in public health, our society has no more than 3,000 ophthalmologists majoring in fundus oculi disease currently. As most of them assembling in metropolitan cities, health system in this field is frail in primary hospitals. Owing to this unreasonable distribution of medical resources, providing medical service to hundreds of millions of potential patients threatened with blindness is almost impossible. To solve this problem, this software (MCS) was developed as a computer-aided diagnosis to help junior ophthalmologists to detect 13 major retina diseases from color fundus photographs. This study has been designed to validate the safety and efficiency of this device.